Idorsia Pharmaceuticals Ltd. has unveiled positive results from the first Phase III study of daridorexant showing that the closely watched drug improved overall sleep and daytime performance of patients with insomnia.
The Swiss group, founded in 2017 by Jean-Paul Clozel with assets not included in the $30bn sale of his biotech Actelion Pharmaceuticals Ltd. to Johnson & Johnson, has published top-line results of the first pivotal trial investigating daridorexant, a dual orexin receptor antagonist
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?